MRNS: Marinus Pharmaceuticals, Inc.
About
Marinus Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and commercialization of neuropsychiatric therapeutics. Its clinical stage drug product candidate, ganaxolone, is a positive allosteric modulator being developed in three different dose forms: intravenous, capsule, and liquid. The company was founded in August 2003 and is headquartered in Radnor, PA.
Current Value
$0.311 Year Return
Current Value
$0.311 Year Return
Key Details
Market Cap
$16.97M
P/E Ratio
-0.12
1Y Stock Return
-94.82%
1Y Revenue Growth
1.63%
Dividend Yield
0.00%
Price to Book
-0.3
Strategies that include MRNS
Stock's related to MRNS
Correlated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| ICLR | 42.68% | $16.15B | -27.84% | 0.00% |
| WEX | 41.92% | $7.10B | +2.88% | 0.00% |
| BYON | 35.52% | $283.64M | -61.81% | 0.00% |
| BHVN | 34.79% | $4.67B | +56.79% | 0.00% |
| PSTX | 28.06% | $269.98M | +6.13% | 0.00% |
| KLTR | 27.16% | $305.38M | +16.57% | 0.00% |
| FUN | 26.46% | $4.60B | -16.51% | 0.00% |
| VCYT | 26.37% | $3.03B | +55.48% | 0.00% |
| NRIX | 26.35% | $1.61B | +269.37% | 0.00% |
| CRM | 26.33% | $309.20B | +44.18% | 0.37% |
| FCN | 26.24% | $7.10B | -10.74% | 0.00% |
| HCAT | 26.19% | $458.79M | 0.00% | 0.00% |
| MBUU | 25.95% | $795.51M | -13.00% | 0.00% |
| RXRX | 25.93% | $1.80B | -4.13% | 0.00% |
| BCH | 25.90% | $11.70B | +6.43% | 0.00% |
| HOOD | 25.76% | $31.15B | +341.60% | 0.00% |
| REXR | 25.57% | $9.55B | -8.36% | 3.81% |
| LOGI | 25.54% | $11.51B | -9.19% | 1.76% |
| EVR | 25.52% | $11.45B | +108.92% | 1.04% |
| PLRX | 25.51% | $778.32M | -9.55% | 0.00% |
Uncorrelated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| VZ | -0.01% | $176.51B | +12.56% | 6.37% |
| ALAR | -0.03% | $89.09M | +158.08% | 0.00% |
| ARQ | 0.03% | $332.89M | +216.80% | 0.00% |
| MFIN | -0.04% | - | - | 4.31% |
| HMST | -0.04% | $215.54M | +82.88% | 0.00% |
| TPB | 0.06% | $1.08B | +167.44% | 0.45% |
| MHK | -0.07% | $8.56B | +61.48% | 0.00% |
| SGC | 0.09% | $261.95M | +41.61% | 4.32% |
| JXN | -0.10% | $7.35B | +117.92% | 2.75% |
| ATMU | -0.10% | $3.57B | +98.98% | 0.23% |
| CATO | 0.11% | $127.11M | -9.52% | 11.00% |
| TCPC | 0.11% | - | - | 15.09% |
| CLLS | 0.13% | $141.30M | -30.99% | 0.00% |
| SCM | -0.13% | - | - | 11.60% |
| BOH | -0.14% | $3.06B | +39.34% | 3.64% |
| LTM | 0.15% | $8.51B | -100.00% | <0.01% |
| JRVR | -0.16% | $168.34M | -52.25% | 4.52% |
| VSTA | 0.19% | $204.94M | -39.33% | 0.00% |
| CASY | 0.20% | $15.28B | +45.52% | 0.45% |
| GBDC | -0.25% | - | - | 10.14% |
Inversely Correlated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| AMSF | -28.84% | $1.11B | +22.66% | 2.52% |
| WST | -26.60% | $22.02B | -13.73% | 0.27% |
| ACIC | -21.71% | $631.49M | +58.21% | 0.00% |
| TMUS | -21.68% | $270.63B | +56.92% | 0.83% |
| CPRI | -18.56% | $2.36B | -58.95% | 0.00% |
| ADT | -17.53% | $6.85B | +26.68% | 2.64% |
| MOH | -16.49% | $16.16B | -21.56% | 0.00% |
| WH | -15.95% | $7.35B | +22.24% | 1.58% |
| EGBN | -14.80% | $861.65M | +20.89% | 5.30% |
| RJF | -14.49% | $33.06B | +55.96% | 1.11% |
| MPW | -13.99% | $2.60B | -4.63% | 12.59% |
| GBX | -13.81% | $2.03B | +73.41% | 1.86% |
| BRFS | -12.92% | $6.90B | +48.76% | 0.00% |
| WHR | -12.47% | $6.05B | +0.98% | 6.44% |
| CLS | -11.65% | $10.10B | +223.71% | 0.00% |
| LNN | -11.25% | $1.35B | +3.22% | 1.14% |
| MTLS | -10.81% | $399.00M | +3.76% | 0.00% |
| CACI | -10.72% | $9.96B | +37.84% | 0.00% |
| HCI | -10.65% | $1.16B | +29.00% | 1.48% |
| CHDN | -10.56% | $10.20B | +15.49% | 0.28% |
ETF's related to MRNS
Correlated ETFs
| Name | Correlation | AUM | Expense Ratio |
|---|---|---|---|
| RSPA | 45.63% | $273.87M | 0% |
| EFAA | 36.50% | $117.38M | 0% |
| ARKK | 31.19% | $6.28B | 0.75% |
| EMHY | 31.07% | $448.75M | 0.5% |
| ARKW | 30.87% | $1.69B | 0.87% |
| PINK | 30.84% | $161.15M | 0.5% |
| FALN | 30.49% | $1.84B | 0.25% |
| WCLD | 30.48% | $454.67M | 0.45% |
| QQA | 30.36% | $135.01M | 0% |
| ARKF | 30.05% | $1.09B | 0.75% |
| VB | 29.15% | $63.63B | 0.05% |
| BLOK | 28.91% | $862.63M | 0.76% |
| VTWO | 28.66% | $12.38B | 0.1% |
| IHAK | 28.41% | $916.89M | 0.47% |
| YYY | 28.18% | $538.03M | 4.6% |
| IWS | 26.55% | $13.85B | 0.23% |
| AOR | 26.52% | $2.20B | 0.15% |
| EPP | 26.43% | $2.00B | 0.48% |
| JHMM | 26.39% | $4.15B | 0.42% |
| PGF | 26.34% | $934.20M | 0.54% |
Uncorrelated ETFs
| Name | Correlation | AUM | Expense Ratio |
|---|---|---|---|
| TPMN | -0.48% | $40.60M | 0.65% |
| DBA | -0.48% | $755.88M | 0.93% |
| DBE | -0.66% | $50.13M | 0.77% |
| DBO | -0.87% | $217.57M | 0.77% |
| KRBN | 0.92% | $242.47M | 0.85% |
| BILZ | 0.95% | $563.02M | 0.14% |
| COMT | 1.05% | $829.06M | 0.48% |
| XHLF | 1.48% | $874.27M | 0.03% |
| CLOI | 1.55% | $715.40M | 0.4% |
| GSG | 1.60% | $914.42M | 0.75% |
| USCI | -1.61% | $185.47M | 1.07% |
| SHV | 1.67% | $18.13B | 0.15% |
| SGOV | 1.92% | $27.53B | 0.09% |
| GBIL | 2.04% | $5.60B | 0.12% |
| FTGC | 2.12% | $2.17B | 1.02% |
| XBIL | -2.19% | $637.70M | 0.15% |
| FMF | -2.44% | $244.61M | 0.95% |
| DBC | 2.57% | $1.39B | 0.87% |
| PDBC | 2.74% | $4.40B | 0.59% |
| DBMF | -2.81% | $1.02B | 0.85% |
Inversely Correlated ETFs
| Name | Correlation | AUM | Expense Ratio |
|---|---|---|---|
| BTAL | -17.36% | $388.04M | 1.43% |
| VIXY | -14.38% | $195.31M | 0.85% |
| TAIL | -9.28% | $67.98M | 0.59% |
| KMLM | -8.83% | $353.87M | 0.9% |
| PHDG | -8.76% | $113.97M | 0.39% |
| EQLS | -8.60% | $76.08M | 1% |
| TBLL | -7.02% | $1.92B | 0.08% |
| IVOL | -6.05% | $548.70M | 1.02% |
| UUP | -5.48% | $309.25M | 0.77% |
| CTA | -5.11% | $350.27M | 0.78% |
| JUCY | -4.87% | $324.29M | 0.6% |
| CCOR | -4.69% | $109.04M | 1.18% |
| USDU | -4.54% | $201.97M | 0.5% |
| WEAT | -4.50% | $120.27M | 0.28% |
| DBMF | -2.81% | $1.02B | 0.85% |
| FMF | -2.44% | $244.61M | 0.95% |
| XBIL | -2.19% | $637.70M | 0.15% |
| USCI | -1.61% | $185.47M | 1.07% |
| DBO | -0.87% | $217.57M | 0.77% |
| DBE | -0.66% | $50.13M | 0.77% |
News
Yahoo
It's been a sad week for Marinus Pharmaceuticals, Inc. ( NASDAQ:MRNS ), who've watched their investment drop 14% to...
Yahoo
Marinus Pharmaceuticals (MRNS) delivered earnings and revenue surprises of 4.55% and 4.59%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Yahoo
RADNOR, Pa. AP) — Marinus Pharmaceuticals Inc. MRNS) on Tuesday reported a loss of $24.2 million in its third quarter.
Yahoo
RADNOR, Pa., November 12, 2024--Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today reported business highlights and financial results for the third quarter ended September 30, 2024.
Yahoo
In response to the findings, Marinus is halting further clinical development of ganaxolone.
Yahoo
The British pharma is making what it calls its largest U.S. manufacturing investment. Elsewhere, AbbVie expanded a longstanding partnership and Marinus said it would lay off staff.
Disclaimer
Information on this page is obtained from our data provider, Xignite, an unaffiliated third party. Double believes the information shown here is reliable, but has not been verified and there is no guarantee that the information is accurate. We also show information based on calculations performed by Double using data from our provider. Double believes this information is reliable, but has not verified the data and there is no guarantee that the calculations are accurate.